Cargando…

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

BACKGROUND: The effect of the combination of an anti-angiogenic agent with a poly (ADP-ribose) polymerase (PARP) inhibitor in cancer treatment is unclear. We assessed the oral combination of fuzuloparib, a PARP inhibitor, and apatinib, a VEGFR2 inhibitor for treating advanced ovarian cancer (OC) or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yaxin, Wang, Wei, Yin, Rutie, Zhang, Youzhong, Zhang, Yu, Zhang, Keqiang, Pan, Hongming, Wang, Ke, Lou, Ge, Li, Guiling, Zhang, Ruyan, Li, Kun, Rao, Jing, Zhang, Ben, Wang, Yuting, Wang, Quanren, Gao, Yunong, Li, Huiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542255/ https://www.ncbi.nlm.nih.gov/pubmed/37775744 http://dx.doi.org/10.1186/s12916-023-03046-8

Ejemplares similares

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2022)

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
por: Wu, Yawen, et al.
Publicado: (2022)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Fuzuloparib: First Approval
por: Lee, Arnold
Publicado: (2021)

Correction to: Fuzuloparib: First Approval
por: Lee, Arnold
Publicado: (2021)

Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
por: Wu, Xiaohua, et al.
Publicado: (2022)

Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
por: Li, Ning, et al.
Publicado: (2022)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
por: Liu, Jieqiong, et al.
Publicado: (2020)

Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer
por: Zhang, Jiayang, et al.
Publicado: (2022)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Overview on population screening for carriers with germline BRCA mutation in China
por: Lei, Huijun, et al.
Publicado: (2022)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
por: Zhang, Yunuo, et al.
Publicado: (2022)

Case Report: Coinheritance of Germline Mutations in APC and BRCA1 in Colorectal Cancer
por: Huang, Wei, et al.
Publicado: (2021)

Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
por: Villarreal-Garza, Cynthia, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Analysis of BRCA Germline Mutations in Chinese Prostate Cancer Patients
por: Chen, Wei, et al.
Publicado: (2022)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
por: Zhang, Li, et al.
Publicado: (2021)

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study
por: Li, Kemin, et al.
Publicado: (2022)

Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report
por: Chen, Dongmei, et al.
Publicado: (2022)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Metzger-Filho, Otto, et al.
Publicado: (2021)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Case Report: Double Germline Mutations in BRCA1 and MSH2 in a Patient With Mixed Serous-Endometrioid Endometrial Carcinoma
por: Zheng, Hong, et al.
Publicado: (2020)

Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer
por: Huang, Xin, et al.
Publicado: (2020)

Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2021)

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
por: Xu, Gehan, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis
por: Li, Huiping, et al.
Publicado: (2021)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

A new pathogenic mutation of the BRCA1 gene in a patient with ovarian cancer: A case report
por: Yizhen, Niu, et al.
Publicado: (2018)

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
por: Wang, Tiantian, et al.
Publicado: (2022)

Characteristics of BRCA1/2 pathogenic germline mutations in chinese NSCLC patients and a comparison with HBOC
por: Xu, Zheyuan, et al.
Publicado: (2021)

High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients
por: Rashid, Muhammad Usman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ufukarla0mdrjo51cdr0rsho3t